Daily FNArena News - Australia

With little end in sight to a weak iron ore price, Arrium has decided to act upon its debt sooner rather than later by announcing a surprise raising. Brokers discuss whether investors should take up their rights.

CSL’s competitor, Baxter, has received US FDA approval for HyQvia and brokers assess the impact on CSL’s rival product, Hizentra.

A wrap of the day’s activity on the Australian stock market.

Several brokers took the axe to Myer’s ratings in the wake of the FY14 results but a few remain optimistic.

Weekly update on recommendation, target price, and earnings forecast changes.

A wrap of the day’s activity on the Australian stock market.

A wrap of the day’s activity on the Australian stock market.

FNArena’s weekly update on short positions in the Australian share market.

FNArena provides a weekly update of Australian listed corporate bond issues, current pricing and yield data.

Brokers warn the Financial System Inquiry will likely mean an end to bank outperformance and increasing capital management.